Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,475Revenue $M64.5Net Margin (%)18.6Z-Score1.3
Enterprise Value $M1,503EPS $0.6Operating Margin %30.4F-Score7
P/E(ttm))132Cash Flow Per Share $0.6Pre-tax Margin (%)17.5Higher ROA y-yY
Price/Book56.110-y EBITDA Growth Rate %0Quick Ratio8.1Cash flow > EarningsY
Price/Sales24.95-y EBITDA Growth Rate %0Current Ratio8.1Lower Leverage y-yN
Price/Cash Flow32.1y-y EBITDA Growth Rate %23.5ROA % (ttm)7.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)7ROE % (ttm)24.1Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M19.6ROI % (ttm)10.2Gross Margin Increase y-yN

Gurus Latest Trades with LGND

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 75.3231%Reduce -99.32%3,766
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 75.3231%Add 132.31%81,908
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 75.3230%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 75.3214%New holding55,492
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 75.3212%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 75.3231%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 75.3240%New holding6,136
LGNDDaniel Loeb 2011-12-31 Sold Out -0.46%$10.59 - $15.73
($12.77)
$ 75.3283%Sold Out0
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 75.3283%Sold Out0
LGNDDaniel Loeb 2011-06-30 Add0.16%$9.56 - $12.02
($10.55)
$ 75.3286%Add 110.73%705,016
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patel SunilDirector 2015-03-19Sell4,591$74.42-3.29view
Berkman Charles SVP, Gen. Counsel & Secretary 2015-03-16Sell11,264$74.54-3.45view
Herman Melanie JDirector of Accounting 2015-03-02Sell535$60.6918.59view
Herman Melanie JDirector of Accounting 2015-02-19Sell510$57.8424.43view
DeSilva Nishan MVP, Corporate Development 2015-02-10Sell2,300$56.3427.74view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-12-31Buy126$45.2359.12view
FOEHR MATTHEW WEVP and COO 2014-12-31Buy46$45.2359.12view
Herman Melanie JDirector of Accounting 2014-12-31Buy103$45.2359.12view
KOZARICH JOHN WDirector 2014-10-15Buy2,000$45.6857.55view
FOEHR MATTHEW WEVP and COO 2014-10-10Buy85$44.9160.25view

Press Releases about LGND :

    Quarterly/Annual Reports about LGND:

    News about LGND:

    Articles On GuruFocus.com
    dick Feb 13 2015 
    Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
    5 Hot Stocks to Consider Now Mar 30 2012 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
    Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
    Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 

    More From Other Websites
    The Best Of The Best: Don't Miss These Top 9 Stocks Mar 25 2015
    Ligand Pharmaceuticals: Biotech's Jack Of All Trades Mar 25 2015
    Biotech Stocks Extend Gains On Good Drug News Mar 19 2015
    Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog Mar 10 2015
    Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene... Mar 09 2015
    Ligand to Present at the 27th Annual Roth Conference on March 9th Mar 03 2015
    Ligand Pharmaceuticals (LGND) Jumps: Stock Rises 15.5% - Tale of the Tape Mar 03 2015
    Ligand to Present at the 27th Annual Roth Conference on March 9th Mar 03 2015
    10-K for Ligand Pharmaceuticals, Inc. Feb 25 2015
    LIGAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 23 2015
    Glaxo Submits Another Revolade Application in the EU - Analyst Blog Feb 09 2015
    Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings - Tale of the Tape Feb 09 2015
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 09 2015
    Ligand meets 4Q profit forecasts Feb 09 2015
    Ligand meets 4Q profit forecasts Feb 09 2015
    Ligand Reports Fourth Quarter and Full Year 2014 Financial Results Feb 09 2015
    Ligand Reports Fourth Quarter and Full Year 2014 Financial Results Feb 09 2015
    Q4 2014 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open Feb 09 2015
    Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog Feb 06 2015
    Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for... Feb 06 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK